(NXTC) NextCure, Inc. Business Model Canvas Research

NextCure, Inc. uses contract manufacturing partners to make antibody and drug material for research and clinical use, while helping move pipeline programs from lab scale to larger batches. These partners also support quality testing and steady supply, which matters as programs advance through development.

• Research and clinical material supply
• Scale-up and batch consistency
• Quality testing and release
• Supply continuity for pipeline programs

NextCure, Inc.’s oncology research collaborators add tumor-biology and immune-regulation expertise that helps validate 2 core targets, LAIR-1 and B7-H4, and deepen translational insight across the pipeline. In 2025, that outside science support was still key for linking lab findings to human tumor data.

• Validate LAIR-1 and B7-H4 targets
• Expand translational tumor insight
• Strengthen immune-regulation studies

NextCure’s biomarker and translational research studies immune-suppression pathways and tumor response signals to match the right patients and measure target biology. This work is central to LAIR-1 and B7-H4, where biomarker readouts help show whether the drug hits the pathway and which tumors are most likely to respond.

• Maps immune-suppression signals
• Selects likely responders
• Tracks LAIR-1 and B7-H4 biology

Regulatory and CMC planning keeps NextCure, Inc. ready for IND maintenance, trial filings, and scale-up, while matching clinical supply to quality rules. This work is central in a clinical-stage model where each program must clear FDA review and manufacturing checks before it can move forward.

• Supports IND updates and trial submissions
• Aligns supply with quality standards
• Prepares manufacturing for scale-up

NextCure’s scientific and clinical data, from preclinical readouts to translational datasets and trial outputs, are the core evidence base that shapes target picks and go/no-go calls. These data also support FDA discussions and partnership talks, where clear efficacy and safety signals matter more than slide decks.

• Drives target selection
• Informs program decisions
• Supports regulators and partners

NextCure, Inc.'s Beltsville, Maryland headquarters, established in 2015, is the company’s main operating base. It supports management, research coordination, and business development, and houses the core team behind the pipeline.

• Founded in 2015
• Central hub for management
• Coordinates research and BD

NC762 is built to target human B7-H4, a tumor-associated immune checkpoint, giving NextCure, Inc. a separate oncology mechanism beyond its other assets. That can widen immunotherapy reach across B7-H4–expressing solid tumors and help address resistant disease.

• Direct B7-H4 targeting
• Distinct oncology mechanism
• Broader tumor coverage

NC525 is NextCure, Inc.'s preclinical LAIR-1 antibody for acute myeloid leukemia, built to hit both blast cells and leukemic stem cells, which are key drivers of relapse. It broadens the pipeline into hematologic malignancy; AML still has about 20,800 new U.S. cases a year, so a stem-cell target can matter.

• Preclinical AML asset
• Targets blasts and stem cells
• Expands hematology pipeline

NextCure, Inc. keeps regulatory agency interaction central to customer relationships, with ongoing FDA and other health-authority dialogue shaping trial approvals, protocol changes, and the path from early development to later-stage testing. This work matters most before pivotal studies, when one agency call can change timelines, endpoints, and cost.

• Supports IND and trial approval steps
• Guides go/no-go development choices
• Reduces late-stage regulatory risk

NextCure maintains its Yale University license obligations to keep access to its foundational technology, which protects IP continuity and program freedom to operate. In its latest filing, this matters because the Company still relies on licensed rights for core R&D, and one lapse could disrupt development across multiple programs.

• Keeps Yale license in good standing
• Protects core IP access
• Supports freedom to operate

NextCure, Inc. uses its corporate website and SEC filings to publish public disclosures, pipeline status, and corporate updates for investors, analysts, and other stakeholders. As a Nasdaq-listed biopharma company, it relies on 10-K, 10-Q, and 8-K reporting to keep the market current on cash use, trial progress, and governance.

• Public source for pipeline and risk updates
• Serves investors and analysts directly
• Core channel for U.S. listed biopharma disclosure

NextCure, Inc. uses partner and business development outreach for licensing, co-development, and financing talks with pharma and biotech groups. For a clinical-stage biotech with no product sales, this channel is a key way to secure non-dilutive capital and strategic support without relying only on equity raises.

• Drives licensing and collaboration deals
• Links NextCure to pharma partners
• Supports non-dilutive funding options

Pharmaceutical and biotech partners are NextCure, Inc.’s main outlet for licensing or co-developing its pipeline assets, especially the company’s three immunotherapy programs built around novel mechanisms. These partners matter most for future deal flow because they can fund development, add trial scale, and move assets from discovery into the clinic.

• Licensees for pipeline assets
• Seek novel immunotherapy mechanisms
• Core to future partnering strategy

Academic and translational researchers study immune-suppression pathways and tumor biology, which helps NextCure, Inc. validate targets outside its labs and find new ones faster. This network also boosts scientific credibility and collaboration depth; NextCure reported no product revenue in fiscal 2024, so external research ties matter for pipeline signal and funding discipline.

• External validation for targets
• New target discovery support
• Builds scientific credibility

Personnel and headquarters costs cover NextCure, Inc.’s scientific, clinical, regulatory, and administrative teams, plus the Beltsville, Maryland base that keeps a multi-program biotech moving. In its 2025 Form 10-K, these costs stayed a core fixed burden, since the Company Name must fund discovery, trial work, compliance, and HQ support at the same time.

• Scientific, clinical, and regulatory staff
• Beltsville, Maryland headquarters support
• Fixed cost load for multi-program biotech

NextCure, Inc. spends on IP, legal, and compliance to protect its patent portfolio, meet licensing terms, and stay current with SEC reporting, regulatory filings, and governance rules. These costs are tied to preserving asset value and keeping clinical and public-company operations running without delays or penalties.

• Patent filings and maintenance
• Licensing and contract compliance
• SEC reporting and governance
• Regulatory submissions and oversight

Future milestone income for NextCure, Inc. would come only when a program clears clinical or regulatory steps, so payments are tied to 0-to-1 development wins, not steady sales. In FY2025, NextCure reported 0 product revenue, so any future partner deal could be a key source of milestone cash if its pipeline advances.

• Paid on development hits
• Depends on partnering deals

NextCure, Inc. future royalties are tied to licensed assets only if a partner pushes them into commercialization, so the cash flow depends on downstream success, not NextCure, Inc. current sales. As of FY2025, this is still a long-term upside stream rather than operating revenue, with no royalty income yet reported.

• Depends on partner launches
• Creates upside after approval
• No current operating revenue